<DOC>
	<DOCNO>NCT01944800</DOCNO>
	<brief_summary>Aim randomize , open-label , multicenter ISAR-REACT 5 trial ass whether ticagrelor superior prasugrel patient acute coronary syndrome plan invasive strategy term clinical outcome .</brief_summary>
	<brief_title>Prospective , Randomized Trial Ticagrelor Versus Prasugrel Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Major Hospitalization acute coronary syndrome ( STsegment elevation myocardial infarction , nonSTsegment elevation myocardial infarction unstable angina pectoris ) plan invasive strategy Major 1. intolerance allergy ticagrelor prasugrel 2. history stroke , transient ischemic attack intracranial bleeding 3. know intracranial neoplasm , intracranial arteriovenous malformation intracranial aneurysm 4. active bleeding , clinical finding , judgement investigator associate increase risk bleed 5. fibrinspecific fibrinolytic therapy le 24 h randomization , nonfibrinspecific fibrinolytic therapy le 48 h randomization 6. know platelet count &lt; 100.000/μL time screen 7. know anemia ( hemoglobin &lt; 10 g/dL ) time screen 8. oral anticoagulation safely discontinue duration study 9 . INR know great 1.5 time screen 10. chronic renal insufficiency require dialysis 11. moderate severe hepatic dysfunction ( Child Pugh B C ) 12. increase risk bradycardia event ( Sick Sinus , AV block grade II III , bradycardiainduced syncope ) 13. index event acute complication ( &lt; 30 day ) PCI 14. concomitant medical illness opinion investigator associate life expectancy &lt; 1 year 15. concomitant oral i.v . therapy strong CYP3A Inhibitors ( e.g . ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , grapefruit juice &gt; 1 L/d ) , CYP3A substrates narrow therapeutic index ( e.g . cyclosporine , quinidine ) , strong CYP3A inducer ( e.g . rifampin/rifampicin , phenytoin , carbamazepine , dexamethason , phenobarbital ) safely discontinue 16 . ≥1 dose ticagrelor prasugrel within 5 day randomisation 17. write informed consent 18. participation another investigational drug study 19. previous enrolment study 20. woman childbearing potential negative pregnancy test agree use reliable method birth control study 21 . Pregnancy , give birth within last 90 day , lactation 22. inability cooperate protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
</DOC>